These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 800324)

  • 1. Immunocompetence, immunodeficiency and prognosis in cancer.
    Hersh EM; Gutterman JU; Mavligit GM; Mountain CW; McBride CM; Brugess MA; Lurie PM; Zelen M; Takita H; Vincent RG
    Ann N Y Acad Sci; 1976; 276():386-406. PubMed ID: 800324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological markers and breast cancer. A multiparametric study. II. Depressed immune competence.
    Mandeville R; Lamoureux G; Legault-Poisson S; Poisson R
    Cancer; 1982 Oct; 50(7):1280-8. PubMed ID: 6980699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor immunology and immunotherapy.
    Herberman RB
    Laryngoscope; 1977 May; 87(5 Pt 1):722-5. PubMed ID: 321899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of immunologic status of patients receiving BCG therapy for malignant disease.
    Gross NJ; Eddie-Quartey AC
    Cancer; 1976 May; 37(5):2183-93. PubMed ID: 769946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial studies of immunocompetence of patients undergoing chemotherapy for acute leukemia.
    Hersh EM; Gutterman JU; Mavligit GM; McCredie KB; Burgess MA; Matthews A; Freireich EJ
    J Clin Invest; 1974 Aug; 54(2):401-8. PubMed ID: 4527189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCG and cancer.
    Bast RC; Zbar B; Borsos T; Rapp HJ
    N Engl J Med; 1974 Jun; 290(26):1458-69. PubMed ID: 4598691
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of oral BCG in the treatment or metastatic malignant melanoma.
    Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
    Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of macrophages in human and experimental tumors.
    Alexander P; Eccles SA; Gauci CL
    Ann N Y Acad Sci; 1976; 276():124-33. PubMed ID: 800321
    [No Abstract]   [Full Text] [Related]  

  • 9. Feasibility study of active immunotherapy in patients with solid tumors.
    Gerner RE; Moore GE
    Cancer; 1976 Jul; 38(1):131-43. PubMed ID: 779950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unspecific cellular immunity before therapy in patients with squamous cell carcinoma of head and neck.
    Bier J; Bitter K; Nicklisch U
    J Maxillofac Surg; 1978 May; 6(2):75-93. PubMed ID: 353210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in patients with melanoma.
    Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
    Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunologic studies in Holstein-Friesian cattle: an immunocompetence profile.
    Kateley JR; Bazzell SJ
    Am J Vet Res; 1978 Oct; 39(10):1683-7. PubMed ID: 362996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological response in patients receiving Corynebacterium parvum therapy.
    Osborn DE; Castro JE
    Clin Oncol; 1977 Jun; 3(2):155-64. PubMed ID: 872468
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
    Schwarz MA; Gutterman JU; Burgess MA; Heilbrun LK; Murphy WK; Bodey GP; Stone E; Turner-Chism V; Hersh EM
    Cancer; 1980 May; 45(10):2506-15. PubMed ID: 7378986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives in immunotherapy of lung cancer.
    Hersh EM; Gutterman JU; Mavligit GM
    Cancer Treat Rev; 1974 Mar; 1(1):65-80. PubMed ID: 4471091
    [No Abstract]   [Full Text] [Related]  

  • 17. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of leukemia.
    Hersh EM; Gutterman JU; Mavligit GM
    Med Clin North Am; 1976 Sep; 60(5):1019-42. PubMed ID: 781412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic studies in lymphoma and leukemia, and exploration of antitumor immunotherapy.
    Sokal JE
    J Surg Oncol; 1973 Jun; 5(6):557-66. PubMed ID: 4589652
    [No Abstract]   [Full Text] [Related]  

  • 20. Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy.
    Lui VK; Karpuchas J; Dent PB; McCulloch PB; Blajchman MA
    Br J Cancer; 1975 Sep; 32(3):323-30. PubMed ID: 1233077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.